pemar 10 mg prolonged-release tablet prolonged-release tablet
tabuk pharmaceutical manufacturing company, saudi arabia - dalfampridine - prolonged-release tablet - 10 mg
tivicay
viiv healthcare bv - dolutegravir - hiv infections - antivirals for systemic use - tivicay is indicated in combination with other anti-retroviral medicinal products for the treatment of human immunodeficiency virus (hiv) infected adults, adolescents and children of at least 6 years of age or older and weighing at least 14 kg.tivicay is indicated in combination with other anti-retroviral medicinal products for the treatment of human immunodeficiency virus (hiv) infected adults, adolescents and children of at least 4 weeks of age or older and weighing at least 3 kg.
juluca
glaxo smith kline (israel) ltd - dolutegravir as sodium; rilpivirine as hydrochloride - film coated tablets - rilpivirine as hydrochloride 25 mg; dolutegravir as sodium 50 mg - dolutegravir and rilpivirine - juluca is indicated for the treatment of human immunodeficiency virus type 1 (hiv-1) infection in adults who are virologically-suppressed (hiv-1 rna <50 copies/ml) on a stable antiretroviral regimen for at least six months with no history of virological failure and no known or suspected resistance to any non-nucleoside reverse transcriptase inhibitor or integrase inhibitor
triumeq
viiv healthcare b.v. - dolutegravir sodium, lamivudine, abacavir (as sulfate) - hiv infections - antivirals for systemic use - triumeq is indicated for the treatment of human immunodeficiency virus (hiv) infected adults, adolescents and children weighing at least 25 kg who are antiretroviral treatment-naïve or are infected with hiv without documented or clinically suspected resistance to any of the three antiretroviral agents in triumeq.
juluca
viiv healthcare b.v. - dolutegravir sodium, rilpivirine hydrochloride - hiv infections - antivirals for systemic use - juluca is indicated for the treatment of human immunodeficiency virus type 1 (hiv-1) infection in adults who are virologically-suppressed (hiv-1 rna
dovato
viiv healthcare b.v. - dolutegravir sodium, lamivudine - hiv infections - antivirals for systemic use - dovato is indicated for the treatment of human immunodeficiency virus type 1 (hiv-1) infection in adults and adolescents above 12 years of age weighing at least 40 kg, with no known or suspected resistance to the integrase inhibitor class, or lamivudine.
tivicay 10 mg
glaxo smith kline (israel) ltd - dolutegravir as sodium - film coated tablets - dolutegravir as sodium 10 mg - dolutegravir - tivicay is indicated in combination with other anti-retroviral medicinal products for the treatment of human immunodeficiency virus (hiv) infected adults, adolescents and children of at least 6 years of age or older and weighing at least 14 kg
tivicay 25 mg
glaxo smith kline (israel) ltd - dolutegravir as sodium - film coated tablets - dolutegravir as sodium 25 mg - dolutegravir - tivicay is indicated in combination with other anti-retroviral medicinal products for the treatment of human immunodeficiency virus (hiv) infected adults, adolescents and children of at least 6 years of age or older and weighing at least 14 kg
tivicay 50 mg
glaxo smith kline (israel) ltd - dolutegravir as sodium - film coated tablets - dolutegravir as sodium 50 mg - dolutegravir - tivicay is indicated in combination with other anti-retroviral medicinal products for the treatment of human immunodeficiency virus (hiv) infected adults, adolescents and children above 6 years of age.
tivicay 50 mg
glaxo smith kline (israel) ltd - dolutegravir as sodium - film coated tablets - dolutegravir as sodium 50 mg - dolutegravir - tivicay is indicated in combination with other anti-retroviral medicinal products for the treatment of human immunodeficiency virus (hiv) infected adults, adolescents and children of at least 6 years of age or older and weighing at least 14 kg.